InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
March 18, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be presenting at this week’s Public Ventures Discovery Day. The event is scheduled for March 19, 2024, in Dallas. During the event, Cybin CEO Doug Drysdale will participate in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
March 15, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of generalized anxiety disorder (“GAD”). The randomized, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
March 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting was regarding CYB003, the company’s deuterated psilocybin analog for the adjunctive treatment of major […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
March 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, hosted a conference call and webcast this morning at 8:30 a.m. ET. According to the announcement, the company provided an update on CYB003, its proprietary deuterated psilocybin analog being developed […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
March 13, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangement involving the company and Exopharm Limited CAN 163 765 991. Tryp securityholders approved the arrangement during the company’s annual […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
February 27, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be spotlighted at next month’s 44th annual TD Cowen Health Care Conference. The three-day event is scheduled for March 4–6, 2024, in Boston. During the conference, Cybin CEO Doug Drysdale […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights
February 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31, 2023, and recent business highlights. “During the past three months, we have continued to make exciting progress […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders
February 9, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991. […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Compounds Receive USPTO Notice of Allowances
February 8, 2024
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NF0), a leading biotechnology company dedicated to transforming mental-health and addiction treatment, has been issued two Notice of Allowances by the United States Patent and Trademark Office (“USPTO”). The allowances are for compounds from the company’s MYCO-005 and MYCO-006 families. MYCO-005 is a novel compound for […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures Two New JP Patents, Further Broadening IP Portfolio in Key Markets
February 7, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that the Japan Patent (“JP”) Office has granted patents 2023-500532 and 2023-533436, which are expected to provide exclusivity until at least 2040 and 2041, respectively. The […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver
January 26, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that it has been granted a pivotal two-cent waiver by the Australian Securities Exchange (“ASX”). According to the announcement, the waiver was also granted to Exopharm […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives FDA Clearance to Begin CYB004 Study for Generalized Anxiety Disorder
January 23, 2024
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received approval from the U.S. Food and Drug Administration (“FDA”) for its investigational new drug (“IND”) application for its proprietary deuterated dimethyltryptamine (“DMT”) molecule: CYB004. The clearance means that Cybin can move […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Topline Data from Phase 1 CYB004 and SPL028 Studies
January 8, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, today announced positive safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data from its phase 1 studies of CYB004 (“IV” administration) and SPL028 (“IV” and “IM” administration) in healthy volunteers. CYB004 and SPL028 […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’
January 8, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has received approval from Australia’s Human Research Ethics Committee (“HREC”) to commence a groundbreaking phase 1 clinical trial of TRP-8803 (IV-infused psilocin) in healthy human volunteers. According […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Eyes Enormous Opportunities Across Its Clinical Development Programs
January 4, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options. The company today outlined its recent positive Phase 2 CYB003 topline results in MDD and near-term milestones across its clinical-stage deuterated psilocybin and dDMT programs in development for the […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Dosing of First Patient in Phase 2a TRP-8802 Clinical Trial
January 4, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that the first patient has been dosed in a phase 2a clinical trial evaluating Tryp’s TRP-8802 in patients with fibromyalgia, which is being […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces USPTO Issues Notice of Allowance for MYCO-005 Compound
December 18, 2023
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice was for MYCOF’s proprietary MYCO-005 compound, “Novel Aza-Substituted Psilocin Analogs and Methods […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited
December 11, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has signed a definitive agreement with Exopharm Limited ACN 163 765 991. The agreement, signed last week, outlines plans for Exopharm to acquire all issued and outstanding common […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Additional US Patent for Proprietary Deuterated Psilocybin Analog Program
December 6, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced that it has been granted a U.S. patent by the United States Patent and Trademark Office (“USPTO”); the patent is in support of Cybin’s CYB003 program. According to the announcement, the newly […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Four Poster Presentations at the 2023 ACNP Annual Meeting
December 5, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options. The company today announced the presentation of four posters at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place in Tampa, Florida, Dec. 3-6, 2023. The presentations include […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Topline Safety, Efficacy Data for MDD Study
November 30, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released positive phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”). According to the announcement, study participants […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program
November 29, 2023
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced clarifications regarding its Special Access Support and Supply Program (“SASSP”). The SASSP is MYCOF’s proprietary program designed to […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement
November 20, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has closed its private placement of unsecured convertible notes for aggregate gross proceeds of AUD$3,215,000, which represents an oversubscription of AUD$215,000 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing
November 20, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that it will discuss its topline phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
November 16, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be hosting a research and development briefing on Nov. 30, 2023, at 10 a.m. ET in New York City. During the event, the company will release topline phase 2 safety and efficacy […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
November 15, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023. The event, hosted by the Society for Neuroscience (“SFN”), is taking place Nov. 11-15, 2022, in Washington, D.C. “It is always exciting […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
November 10, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced a firm commitment underwritten offering of 66,666,667 units of CYBN to one of its largest existing institutional shareholders and new institutional investors at a price […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
November 3, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the announcement, Cybin CEO Doug Drysdale is slated to participate on a panel about innovations in mental health care; […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement
November 2, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced a private placement of unsecured convertible notes. The placement is for of up to AUD$3 million and includes the ability to accept oversubscriptions of up to […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Breakthrough Results of Phase 2 Study of MDD Treatment
November 2, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting on interim results from its phase 2 study of CYB003, the company’s proprietary deuterated psilocybin analog, designed to treat major depressive disorder (“MDD”). According to the announcement, the results demonstrate […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
November 1, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its development pipeline. Those milestones for CYB003, the company’s deuterated psilocybin analog program, include the completion of phase 2 topline safety and […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
October 31, 2023
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has filed a shelf prospectus supplement to its Final Short Form Base Shelf Prospectus for the province of Québec and its Amended and […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder
October 31, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
October 26, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs. “Maintaining a secure intellectual property […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
October 26, 2023
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has released a fourth-quarter 2023 company update. According to the update, the company has worked to simplify its business model, streamline workflow and […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
October 25, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has been granted two patents by the United States Patent and Trademark Office; the patents offer protection for the company’s deuterated N, N-dimethyltryptamine (“DMT”) program, including deuterated analogs of DMT related to composition […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to the terms of an arrangement agreement dated Aug. 28, 2023, […]
InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector
October 18, 2023
Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
October 13, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was held Oct. 12, 2023. According to the announcement, 66 shareholders attended the meeting, either in person or by […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement
October 12, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed its previously announced private placement of unsecured convertible debentures to Jason Carroll, Tryp’s newly appointed CEO. The private placement was for gross proceeds of AUD$175,000. Tryp […]